Oncology Target Articles & Analysis
10 articles found
Elevated CCR1 expression correlates with disease severity, suggesting it could serve as both biomarker and therapeutic target. In oncology, CCR1-mediated chemotaxis is increasingly recognized as a driver of the tumor microenvironment. ...
Additionally, PEGylation protects proteins from aggregation and denaturation, improving shelf-life. 4. Enhanced Tumor Targeting (Passive Accumulation) In oncology, PEGylated drugs benefit from the Enhanced Permeability and Retention (EPR) effect, where leaky tumor vasculature allows selective accumulation of macromolecules. ...
Since then, the BCL2 protein has become a key target in oncology and molecular biology. Functions and Roles in the Body Proteins encoded by the BCL2 gene family function primarily at the mitochondrial membrane, where they regulate the release of cytochrome c—a crucial step in the apoptotic process. ...
These findings suggest potential avenues for therapeutic intervention targeting neuroinflammation. However, the clinical translation of chemokine-based therapies is fraught with challenges. ...
These specialized compounds often target cancer by interfering with cell division, signal transduction, or angiogenesis processes. Modern oncology APIs include targeted therapies like kinase inhibitors and monoclonal antibodies that precisely attack cancer cells while minimizing damage to healthy tissues. ...
Alfa Cytology has revealed new FAP-targeted therapeutics development services that aim to develop precise and effective cancer treatments. ...
These therapeutic antibodies aim to specifically target antigens on the surface of cells and bind to them, leading to acidic reactions that result in the destruction of target cells. ...
Implications of Epigenetics in Therapeutic and Research Domains In the field of oncology, it bears vast potential for targeted therapies. Aberrant epigenetic processes often play a significant role in the onset and progression of various cancers. ...
A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of Perugia.The breakthrough drug discovery strategy pioneered by Sibylla in this study would not only promise to reduce the risk of drug resistance and harmful side effects, ...
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. While this nomination is a potentially important development for the ongoing COVID-19 pandemic ...